Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476M [Seeking Alpha]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Seeking Alpha
Suzhou Alphamab Oncology partners with ArriVent BioPharma to develop antibody drug conjugates, potentially receiving up to $615.5 million in milestones. Summit Therapeutics expands its rights to Akeso's ivonescimab and raises $200 million in a private placement. Deals and Financings Structure Therapeutics ( GPCR ), a San Francisco-Shanghai clinical stage company, had a busy week, announcing positive clinical results for its obesity drug and then raising $476 million via an offering of its ADSs (see Recommended For You Recommended For You
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- ArriVent BioPharma, Inc. (NASDAQ: AVBP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.MarketBeat
- Alphamab Oncology Collaborated with ArriVent in relation to the Research, Development and Commercialization of ADC Products [Yahoo! Finance]Yahoo! Finance
- ArriVent Announces a Multi-Target ADC Collaboration with Alphamab [Yahoo! Finance]Yahoo! Finance
- ArriVent Announces a Multi-Target ADC Collaboration with AlphamabGlobeNewswire
- ArriVent Appoints John Hohneker, M.D., to its Board of DirectorsGlobeNewswire
AVBP
Sec Filings
- 6/5/24 - Form 8-K
- 5/20/24 - Form 4
- 5/20/24 - Form 3
- AVBP's page on the SEC website